Cargando…

FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications

This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lawrence X., Raw, Andre, Wu, Larisa, Capacci-Daniel, Christina, Zhang, Ying, Rosencrance, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733282/
https://www.ncbi.nlm.nih.gov/pubmed/31517275
http://dx.doi.org/10.1016/j.ijpx.2019.100010
_version_ 1783449951547686912
author Yu, Lawrence X.
Raw, Andre
Wu, Larisa
Capacci-Daniel, Christina
Zhang, Ying
Rosencrance, Susan
author_facet Yu, Lawrence X.
Raw, Andre
Wu, Larisa
Capacci-Daniel, Christina
Zhang, Ying
Rosencrance, Susan
author_sort Yu, Lawrence X.
collection PubMed
description This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, control, and communication; 3) perform computer-aided analyses of applications to compare regulatory standards and quality risks across applications and facilities; and 4) provide a structured assessment that minimizes text-based narratives and summarization of provided information. When fully developed and implemented, KASA will enrich the effectiveness, efficiency, and consistency of regulatory quality oversight through lifecycle management of products and facilities, and information sharing in a standardized and structured format. Ultimately, KASA will advance FDA’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs.
format Online
Article
Text
id pubmed-6733282
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67332822019-09-12 FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications Yu, Lawrence X. Raw, Andre Wu, Larisa Capacci-Daniel, Christina Zhang, Ying Rosencrance, Susan Int J Pharm X Article This paper describes a new FDA’s pharmaceutical quality assessment system: Knowledge-aided Assessment & Structured Application (KASA). The KASA system is designed to: 1) capture and manage knowledge during the lifecycle of a drug product; 2) establish rules and algorithms for risk assessment, control, and communication; 3) perform computer-aided analyses of applications to compare regulatory standards and quality risks across applications and facilities; and 4) provide a structured assessment that minimizes text-based narratives and summarization of provided information. When fully developed and implemented, KASA will enrich the effectiveness, efficiency, and consistency of regulatory quality oversight through lifecycle management of products and facilities, and information sharing in a standardized and structured format. Ultimately, KASA will advance FDA’s focus on pharmaceutical quality, the foundation for ensuring the safety and efficacy of drugs. Elsevier 2019-03-17 /pmc/articles/PMC6733282/ /pubmed/31517275 http://dx.doi.org/10.1016/j.ijpx.2019.100010 Text en Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Yu, Lawrence X.
Raw, Andre
Wu, Larisa
Capacci-Daniel, Christina
Zhang, Ying
Rosencrance, Susan
FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
title FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
title_full FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
title_fullStr FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
title_full_unstemmed FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
title_short FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
title_sort fda’s new pharmaceutical quality initiative: knowledge-aided assessment & structured applications
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733282/
https://www.ncbi.nlm.nih.gov/pubmed/31517275
http://dx.doi.org/10.1016/j.ijpx.2019.100010
work_keys_str_mv AT yulawrencex fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications
AT rawandre fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications
AT wularisa fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications
AT capaccidanielchristina fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications
AT zhangying fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications
AT rosencrancesusan fdasnewpharmaceuticalqualityinitiativeknowledgeaidedassessmentstructuredapplications